Tyrosine Hydroxylase Deficiency: From Clinical and Therapeutic Features to Pathogenetic Considerations

Yoshiaki Furukawa · 2026

Read Tyrosine Hydroxylase Deficiency: From Clinical and Therapeutic Features to Pathogenetic Considerations by Yoshiaki Furukawa (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/openalex-w7220696744.txt.

Description

Yoshiaki Furukawa reviewed tyrosine hydroxylase deficiency in a 2026 article for a Japanese medical journal. The rare inherited disorder comes from bad variants in both copies of a gene whose enzyme performs the rate-limiting step in making dopamine and related messengers. With that step broken, patients lack dopamine first and the adrenaline family second, and most respond well to levodopa, the standard replacement therapy.

Its spectrum is very broad, and recent evidence shows why. There is no degeneration of dopamine neurons. Mildly affected patients may develop dopa-responsive dystonia through faulty receptor signaling after congenital dopamine shortage. Severely affected infants show major motor delay and react too strongly to levodopa. Because this brain system matures after birth, he argues, treatment should start as early as possible, starting such babies on very low levodopa doses to avoid intolerable side effects.

Catalog record

CREATORYoshiaki Furukawa
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE56 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEOpenAlex / Juntendō Igaku/Juntendo igaku

Source: https://doi.org/10.14789/ejmj.jmj26-0055-r

Browse the full library · About the Tower of Babel